Compared with the placebo group, the Midostaurin group significantly prolonged OS (74.7 months vs. 25.6 months) and EFS (8.2 months vs. 3.0 months), but there was no significant difference in CR (58.9% vs. 53.5%), and the incidence of adverse events was similar to the placebo group, indicating that Midostaurin combined chemotherapy plan can significantly improve the survival prognosis of AML patients carrying FLT3 mutations [90]. Here, FLT3 is linked to acute myeloid leukemia.